Color vision impairments in schizophrenia and the role of antipsychotic medication type.

Schizophrenia patients (SCZ) demonstrate deficits in many domains of mental functioning, including visual perception. An issue that has been relatively unexplored, in terms of explaining variation in visual function in SCZ, however, is medication use. The present study explored potential medication effects on color vision in SCZ, a process that is strongly linked to dopaminergic function in the retina.

Psychophysical evaluation of contrast sensitivity using Gabor patches in tobacco addiction.

This study, an extension of Fernandes et al. (2017), provided consistent contrast sensitivity function (CSF) measurements in a large sample. CSF was assessed for luminance stimuli in different 48 chronic smokers and 50 healthy nonsmokers.

Tobacco Use Decreases Visual Sensitivity in Schizophrenia.

Smoking prevalence in patients who are diagnosed with schizophrenia (SCZ) is higher than in the general population. Chronic tobacco use in SCZ patients may reduce the side effects of antipsychotic drugs, thus serving as a self-medication for such side effects. Understanding the ways in which chronic tobacco use influences visual sensitivity has clinical implications, which may serve as a tool for non-invasively diagnosing early-stage visual processing deficits.

Colour discrimination thresholds in type 1 Bipolar Disorder: a pilot study.

Although some studies have reported perceptual changes in psychosis, no definitive conclusions have been drawn about visual disturbances that are related to bipolar disorder (BPD). The purpose of the present study was to evaluate colour vision in BPD patients. Data were recorded from 24 participants: healthy control group (n = 12) and type 1 BPD group (n = 12).